LeMaitre Vascular Inc. Common Stock (LMAT)
Stock · NASDAQ · Health Care
$80.84as of 10/16/2026
Price chart
Active signals
LMAT Signal Track Record
How signals performed across all stocks →What LMAT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | +1.3% | 53% | September 9, 2026 |
| Bollinger Band Breakout | 26 | +0.9% | 54% | September 28, 2026 |
| 200-Day Moving Average TouchActive now | 26 | +0.9% | 58% | July 24, 2026 |
| Bollinger Band Breakdown | 20 | +2.4% | 60% | August 5, 2026 |
| Any 20-session window (baseline) | +1.7% | 59% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About LMAT
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy ca…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 646
- Website
- www.lemaitre.com/
Fundamentals
- 1-day range
- $82.87$84.66
- Market cap
- $1.85B
- P/E (trailing)
- 29.17
- P/E (forward)
- 26.16
- EPS (trailing)
- $2.77
- Dividend yield
- 1.05%
- Beta
- 0.50
- Avg. volume
- 327.5K
- Ex-dividend date
- August 20, 2026
- Dividend pay date
- September 3, 2026
How LeMaitre Vascular Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
7 analyst ratings
LeMaitre Vascular Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- LMATLeMaitre Vascular Inc. Common Stock$80.82▼ 2.81%Market cap $1.85BP/E 29.17$78.22$118.01
- NVCRNovoCure Limited Ordinary Shares$14.07▼ 2.36%Market cap $1.83BP/E —$9.82$21.45
- INSPInspire Medical Systems Inc. Common Stock$68.79▼ 1.90%Market cap $1.70BP/E 15.06$38.91$147.03
- ATRCAtriCure Inc. Common Stock$56.07▼ 2.96%Market cap $2.01BP/E 261.42$25.36$61.7
- KMTSKestra Medical Technologies Ltd. Common Stock$27.24▼ 5.02%Market cap $1.48BP/E —$17.34$30
- ATECAlphatec Holdings Inc. Common Stock$10.46▼ 4.30%Market cap $1.42BP/E —$6.82$23.29
- HTFLHeartflow Inc. Common Stock$48.29▼ 5.14%Market cap $2.34BP/E —$20.13$54.32
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| LMAT LeMaitre Vascular Inc. Common Stock | $1.85B | 29.17 | $80.82 | ▼ 2.81% | $78.22$118.01 |
| NVCR NovoCure Limited Ordinary Shares | $1.83B | — | $14.07 | ▼ 2.36% | $9.82$21.45 |
| INSP Inspire Medical Systems Inc. Common Stock | $1.70B | 15.06 | $68.79 | ▼ 1.90% | $38.91$147.03 |
| ATRC AtriCure Inc. Common Stock | $2.01B | 261.42 | $56.07 | ▼ 2.96% | $25.36$61.7 |
| KMTS Kestra Medical Technologies Ltd. Common Stock | $1.48B | — | $27.24 | ▼ 5.02% | $17.34$30 |
| ATEC Alphatec Holdings Inc. Common Stock | $1.42B | — | $10.46 | ▼ 4.30% | $6.82$23.29 |
| HTFL Heartflow Inc. Common Stock | $2.34B | — | $48.29 | ▼ 5.14% | $20.13$54.32 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- LeMaitre Vascular (NASDAQ:LMAT): A Quality Stock for Long-Term InvestorsChartMill · 10/9/2026
- 1 of Wall Street’s Favorite Stocks to Own for Decades and 2 We Brush OffYahoo · 10/6/2026
- LeMaitre Vascular: The Q2 Miss Hides A Stronger Acquisition MachineSeekingAlpha · 10/1/2026
- Is LeMaitre Vascular (LMAT) A Bargain Following Its 90 Day Pullback?Yahoo · 9/24/2026
- LeMaitre Vascular (LMAT) Stock Looks Fully Priced On Its 57% Five Year RunYahoo · 9/24/2026
- 3 Small-Cap Stocks We Steer Clear OfYahoo · 9/22/2026
- 2 Profitable Stocks to Target This Week and 1 We IgnoreYahoo · 9/21/2026
Insider Activity
Insider Actions →- David B. Roberts · September 3, 2026 · Grant5
- David B. Roberts · September 3, 2026 · Grant0
- David B. Roberts · September 3, 2026 · Grant4
- David B. Roberts · September 3, 2026 · Grant3
- David B. Roberts · September 3, 2026 · Grant2
- Joseph P. Pellegrino Jr. · September 3, 2026 · Grant2
- Joseph P. Pellegrino Jr. · September 3, 2026 · Grant4
- Lawrence J. Jasinski · September 3, 2026 · Grant2
- Lawrence J. Jasinski · September 3, 2026 · Grant1
- Martha Shadan · September 3, 2026 · Grant2
- Martha Shadan · September 3, 2026 · Grant1
- John James O'Connor · September 3, 2026 · Grant2
- John James O'Connor · September 3, 2026 · Grant1
- Dorian Paul LeBlanc · September 3, 2026 · Grant4
- Dorian Paul LeBlanc · September 3, 2026 · Grant3
Institutional Ownership
March 31, 2026
- Total shares held
- 21.29M
- Total value held
- $2.25B
- Institutional holders
- 332
- Unknown3.14M
- Unknown1.48M
- Unknown998.1K
- Unknown912.1K
- Unknown870.7K
- Unknown855.8K
- Unknown834.5K
- Unknown754.0K
- Unknown658.4K
- Unknown476.3K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
LeMaitre Vascular Highlighted as Long-Term Holding Candidate
Recent articles from ChartMill and Yahoo Finance have identified LeMaitre Vascular as a potential long-term holding. These pieces position the medical device maker as a quality stock suitable for investors seeking stability over decades. The commentary reflects a focus on the company's fundamental profile rather than short-term price movements.
LeMaitre Vascular Highlighted as Long-Term Holding Candidate. Recent articles from ChartMill and Yahoo Finance have identified LeMaitre Vascular as a potential long-term holding. These pieces position the medical device maker as a quality stock suitable for investors seeking stability over decades. The commentary reflects a focus on the company's fundamental profile rather than short-term price movements.